deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03217591

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors

Sponsor: Akebia Therapeutics

Interventions IW-1973 Placebo
Updated 15 times since 2017 Last updated: Aug 18, 2022 Started: Aug 1, 2017 Primary completion: Aug 20, 2019 Completion: Aug 20, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Type 2 Diabetes Mellitus With Diabetic Nephropathy, this trial is completed. The trial is conducted by Akebia Therapeutics and has accumulated 15 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Aug 2017 – ~Jan 2018 · 5 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~May 2019 · 9 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Aug 2020 · 10 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

15 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE2

Show 10 earlier versions
  1. Mar 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE2

  3. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE2

  4. Oct 2019 — Aug 2020 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  5. Jun 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  6. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  7. Aug 2018 — May 2019 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  9. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  10. Aug 2017 — Jan 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Akebia Therapeutics
  • Cyclerion Therapeutics
Data source: Akebia Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .